NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D

Open source

DOI
10.1016/j.esmoop.2025.106043
Published
2026 Mar
Container
ESMO open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2025.106043,
  title = {NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.},
  author = {Macarulla T and Cid RP and Womack MS and Gracian AC and Zervoudakis A and Hatoum H and Chung V and Patel A and Paulson AS and Pant S and O'Reilly EM and Hubner RA and Van Cutsem E and Bekaii-Saab T and Zhang L and Li J and Chen H and Maxwell F and Wainberg ZA and Melisi D},
  year = {2026},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2025.106043},
  url = {https://doi.org/10.1016/j.esmoop.2025.106043}
}

RIS

TY  - JOUR
TI  - NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.
AU  - Macarulla T
AU  - Cid RP
AU  - Womack MS
AU  - Gracian AC
AU  - Zervoudakis A
AU  - Hatoum H
AU  - Chung V
AU  - Patel A
AU  - Paulson AS
AU  - Pant S
AU  - O'Reilly EM
AU  - Hubner RA
AU  - Van Cutsem E
AU  - Bekaii-Saab T
AU  - Zhang L
AU  - Li J
AU  - Chen H
AU  - Maxwell F
AU  - Wainberg ZA
AU  - Melisi D
PY  - 2026
JO  - ESMO open
DO  - 10.1016/j.esmoop.2025.106043
UR  - https://doi.org/10.1016/j.esmoop.2025.106043
ER  - 

APA

T, M., RP, C., MS, W., AC, G., A, Z., H, H., V, C., A, P., AS, P., S, P., EM, O., RA, H., E, V. C., T, B., L, Z., J, L., H, C., F, M., ZA, W., & D, M. (2026). NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.. ESMO open. https://doi.org/10.1016/j.esmoop.2025.106043

Source records